Exploring phenotype patterns of breast cancer within somatic mutations: a modicum in the intrinsic code

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Briefings Bioinform.

• Publication date

  2016-05-19

• Fields of study

  Biology, Medicine, Computer Science

• Identifiers
  DOI 10.1093/bib/bbw040PMID 27197545
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detecting Plasma Tumor DNA in Early-Stage Breast Cancer—Letter

  2015cited by this paper
• Recursive Partitioning and Regression Trees

  2015cited by this paper
• Genotype/Phenotype Correlations in Patients with Hereditary Breast Cancer

  2015cited by this paper
• Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing

  2015cited by this paper
• BRCA1‐like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential

  2015cited by this paper
• Triple-negative breast cancer: molecular subtypes and new targets for therapy.

  2015cited by this paper
• Association of the Alu insertion polymorphism in the progesterone receptor gene with breast cancer in a Mexican population

  2015cited by this paper
• Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response

  2015cited by this paper
• Heterogeneity of Breast Cancer Associations with Common Genetic Variants in FGFR2 according to the Intrinsic Subtypes in Southern Han Chinese Women

  2015cited by this paper
• Mechanisms of aromatase inhibitor resistance

  2015cited by this paper
• Exome Analysis Reveals Differentially Mutated Gene Signatures of Stage, Grade and Subtype in Breast Cancers

  2015cited by this paper
• Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer

  2015cited by this paper
• Germline RECQL mutations are associated with breast cancer susceptibility

  2015cited by this paper
• Analysis of PIK3CA Mutations in Breast Cancer Subtypes

  2014cited by this paper
• Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences

  2014cited by this paper
• PIK3CA and TP53 Gene Mutations in Human Breast Cancer Tumors Frequently Detected by Ion Torrent DNA Sequencing

  2014influential reference
• Biological subtypes of breast cancer: Prognostic and therapeutic implications.

  2014cited by this paper
• C-kit and PDGFRA gene mutations in triple negative breast cancer.

  2014cited by this paper
• SF3B1 mutations constitute a novel therapeutic target in breast cancer

  2014cited by this paper
• R: A language and environment for statistical computing.

  2014cited by this paper
• Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin.

  2014cited by this paper
• PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

  2014cited by this paper
• TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

  2014cited by this paper
• A DNA methylation‐based definition of biologically distinct breast cancer subtypes

  2014cited by this paper
• PIK3CA and APC mutations are synergistic in the development of intestinal cancers

  2014cited by this paper
• Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes

  2014cited by this paper
• Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status

  2014cited by this paper
• PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

  2014cited by this paper
• High EGFR gene copy number predicts poor outcome in triple-negative breast cancer

  2014cited by this paper
• Mutational signatures: the patterns of somatic mutations hidden in cancer genomes

  2014cited by this paper
• Bladder cancer specific pathway interaction networks

  2013cited by this paper
• p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors

  2013cited by this paper
• Hereditary Breast Cancer: The Era of New Susceptibility Genes

  2013cited by this paper
• Molecular Pathways Molecular Pathways : PI 3 K Pathway Targets in Triple-Negative Breast Cancers

  2013cited by this paper
• Statistical significance of combinatorial regulations

  2013cited by this paper
• A survey of tools for variant analysis of next-generation genome sequencing data

  2013cited by this paper
• Master regulators of FGFR2 signalling and breast cancer risk

  2013cited by this paper
• Mutational landscape and significance across 12 major cancer types

  2013cited by this paper
• Data, information, knowledge and principle: back to metabolism in KEGG

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• Genotype in BRCA‐associated Breast Cancers

  2013cited by this paper
• iCOGS collection provides a collaborative model

  2013cited by this paper
• Prognostic and Predictive Significance of MYC and KRAS Alterations in Breast Cancer from Women Treated with Neoadjuvant Chemotherapy

  2013cited by this paper
• PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines

  2013cited by this paper
• Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

  2013cited by this paper
• p53 in breast cancer subtypes and new insights into response to chemotherapy.

  2013cited by this paper
• The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis

  2013cited by this paper
• Emerging patterns of somatic mutations in cancer

  2013cited by this paper
• Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective.

  2012cited by this paper
• Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer

  2012cited by this paper
• Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

  2012cited by this paper
• Emerging targeted therapies in triple-negative breast cancer.

  2012cited by this paper
• Sequence analysis of mutations and translocations across breast cancer subtypes

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• The rebel angel: mutant p53 as the driving oncogene in breast cancer

  2012cited by this paper
• Death and dying: what the patient wants.

  2012cited by this paper
• Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer

  2012cited by this paper
• The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

  2012cited by this paper
• The clonal and mutational evolution spectrum of primary triple-negative breast cancers

  2012cited by this paper
• p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features.

  2011cited by this paper
• Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis

  2011cited by this paper
• Common Genetic Variants Associated with Breast Cancer in Korean Women and Differential Susceptibility According to Intrinsic Subtype

  2011cited by this paper
• Phenotype-Genotype Correlation in Familial Breast Cancer

  2011cited by this paper
• Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast Carcinoma

  2011cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features

  2010cited by this paper
• Triple‐negative breast cancer: Present challenges and new perspectives

  2010cited by this paper
• Mutated genes, pathways and processes in tumours

  2010cited by this paper
• Directed therapy of subtypes of triple-negative breast cancer.

  2010cited by this paper
• Clinical outcomes and correlates of TP53 mutations and cancer.

  2010cited by this paper
• Directed therapy of subtypes of triple-negative breast cancer.

  2010cited by this paper
• Clinical trials in triple negative breast cancer.

  2010cited by this paper
• Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

  2009cited by this paper
• Predicting protein-protein interactions in Arabidopsis thaliana through integration of orthology, gene ontology and co-expression

  2009cited by this paper
• PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches

  2009cited by this paper
• Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival

  2009cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009cited by this paper
• Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics

  2008cited by this paper
• DNA copy number alterations and expression of relevant genes in triple‐negative breast cancer

  2008cited by this paper
• Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

  2008cited by this paper
• An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

  2008cited by this paper
• Triple-Negative Breast Cancer: Risk Factors to Potential Targets

  2008cited by this paper
• FGFR2 Is a Breast Cancer Susceptibility Gene in Jewish and Arab Israeli Populations

  2008cited by this paper
• Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype

  2007cited by this paper
• TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer

  2007cited by this paper
• Unbiased Recursive Partitioning: A Conditional Inference Framework

  2006cited by this paper
• Strong evidence that the common variant S384F in BRCA2 has no pathogenic relevance in hereditary breast cancer

  2005cited by this paper
• Ductal carcinoma in situ (DCIS): are we overdetecting it?

  2004cited by this paper
• Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer

  2003cited by this paper
• Variation in BRCA1 cancer risks by mutation position.

  2002cited by this paper
• Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients

  2000cited by this paper
• Estimating the number of clusters in a dataset via the gap statistic

  2000cited by this paper

• Phenotypic Heterogeneity

  2020cites this paper
• A Bioinformatics Approach for Understanding Genotype–Phenotype Correlation in Breast Cancer

  2016cites this paper